Malignant pure mesenchymal uterine tumours encompass endometrial stromal sarcoma
(ESS), uterine leiomyosarcoma, and undifferentiated sarcomas. This Review discusses …

Gastrointestinal stromal tumours are the most common mesenchymal neoplasm of the
gastrointestinal tract and are highly resistant to conventional chemotherapy and …

Accurate risk stratification of gastrointestinal stromal tumors (GISTs) has become
increasingly important owing to emerging adjuvant systemic treatments. All GISTs have …

Purpose To assess potential differences in progression-free or overall survival when
imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors …

Gastrointestinal stromal tumors (GIST) harbor driver mutations of signal transduction kinases
such as KIT, or, alternatively, manifest loss-of-function defects in the mitochondrial succinate …

Imatinib at 400 mg daily is standard treatment for chronic myeloid leukemia in chronic
phase. We here describe the correlation of imatinib trough plasma concentrations (Cmins) …

Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of
mesenchymal origin and a compelling clinical and biologic model for the rational …

This article is part of a combined publication that expresses the current view of the European
Society of Gastrointestinal Endoscopy (ESGE) about endoscopic ultrasound (EUS)-guided …

Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of
mesenchymal origin. GIST spans a wide clinical spectrum that ranges from tumors with …

Objective: Gastric gastrointestinal stromal tumors (GISTs) are rare neoplasms that require
excision for cure. Although the feasibility of minimally invasive resection of gastric GIST has …